CME · XBRL financial data
Cme Group financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (CME's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,439* | 1,488 | 1,533 | 1,584 | 1,525* | 1,642 | 1,692 | 1,538 | 1,649* | 1,880 | 1,706 | 1,737 |
| Operating income (loss) | 863* | 960 | 1,001 | 1,024 | 947* | 1,108 | 1,129 | 973 | 1,020* | 1,310 | 1,107 | 1,141 |
| Other income (expense) | (961)* | (965) | (937) | (920) | (838)* | (802) | (1,372) | (1,397) | (1,262)* | (1,247) | (1,263) | (1,264) |
| Income tax expense (benefit) | 191* | 258 | 271 | 264 | 222* | 289 | 305 | 269 | 396* | 357 | 286 | 318 |
| Net income (loss) | year only | — | — | — | year only | — | 1,025 | 908 | 1,183* | — | 1,042 | 1,037 |
| Earnings per share, basic USD per share | — | 2.35 | 2.43 | 2.51 | — | 2.63 | 2.81 | 2.49 | 3.29* | 3.25 | 2.89 | 2.90 |
| Earnings per share, diluted USD per share | — | 2.35 | 2.42 | 2.50 | — | 2.62 | 2.81 | 2.49 | 3.28* | 3.18 | 2.88 | 2.89 |
| Weighted average shares, basic millions of shares | 359* | 359 | 359 | 359 | 360* | 360 | 360 | 360 | 360* | 359 | 361 | 358 |
| Weighted average shares, diluted millions of shares | 360* | 360 | 360 | 360 | 360* | 360 | 360 | 360 | 360* | 363 | 361 | 359 |
Balance sheet
CSVFiscal quarters (CME's year ends in late December)
Cash flows
CSVFiscal quarters (CME's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | year only | — | — | — | year only | — | 1,025 | 908 | 1,183* | — | 1,042 | 1,037 |
| Stock-based compensation | 24* | 23 | 19* | 20* | 27* | 21 | 21* | 24* | 29* | 22 | 25* | 24* |
| Net cash from operating activities | 1,044* | 893 | 777* | 1,003* | 1,018* | 1,117 | 1,059* | 968* | 1,134* | 1,260 | 947* | 1,086* |
| Purchases of property and equipment | 21* | 20 | 18* | 30* | 26* | 14 | 18* | 18* | 33* | 22 | 24* | 16* |
| Net cash from investing activities | (20)* | (23) | (5)* | (30)* | (25)* | (16) | (18)* | (19)* | 1,552* | (23) | (29)* | (21)* |
| Dividends paid | 400* | 2,328 | 419* | 419* | 419* | 2,567 | 455* | 455* | 455* | 2,698 | 468* | 465* |
| Repayments of long-term debt | — | 0 | 0* | 0* | — | 750 | 0* | 0* | — | 0 | 0* | 0* |
| Net cash from financing activities | 2,589* | 1,936 | (9,223)* | 13,347* | (984)* | 19,211 | 20,999* | 6,400* | 9,899* | 2,117 | (8,091)* | (3,943)* |
| Net change in cash | 3,612* | 2,806 | (8,451)* | 14,321* | 9* | 20,312 | 22,040* | 7,349* | 12,585* | 3,353 | (7,174)* | (2,878)* |
Compare with peers
SIC 6200 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 6200 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Cme Group | 2,199 | 1,737 | 1,086* | not reported | 10-QSep 30, 2026 |
| Intercontinental Exchange | 936 | 3,630 | 1,162* | 558.9M | 10-QSep 30, 2026 |
| Nasdaq | 365 | 2,393 | 521* | 555.0M | 10-QSep 30, 2026 |
| LPL Financial Holdings | 1,059 | 5,344 | 297* | 77.9M | 10-QSep 30, 2026 |
| Cboe Global Markets | 2,663 | 1,359 | 817* | 104.3M | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.